Key Stats for CYTK Stock
- Price Change for CYTK stock: -10.29%
- CYTK Share Price as of Feb. 25: $62.89
- 52-Week High: $71
- CYTK Stock Price Target: $91
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)>>>
What Happened?
Cytokinetics, Incorporated (CYTK) stock dropped about 10% after the company reported Q4 2025 results that showed a wider net loss. Net loss for the quarter reached roughly 183 million, with basic EPS of -1.5. For the full-year 2025, the company’s loss expanded as R&D and SG&A increased to support late-stage trials and commercialization.
The market also reacted to 2026 guidance that called for combined GAAP R&D and SG&A expenses in the high hundreds of millions. Management signaled that it plans to keep investing heavily in MYQORZO and the broader pipeline.
That outlook raised concerns about additional financing needs and potential dilution. As a result, the stock sold off even though key regulatory milestones had recently gone CYTK’s way.
Despite the negative reaction, CYTK’s recent news flow includes major approvals for MYQORZO, also known as aficamten. In December 2025, the U.S. FDA approved MYQORZO for adults with symptomatic obstructive hypertrophic cardiomyopathy to improve exercise capacity and symptoms.
Then, in February 2026, the European Commission approved MYQORZO in the same indication, with the first European launch expected in Germany in 2026. These approvals mark a pivotal shift as CYTK transitions from a pure development story to a commercial-stage biotech.
See analysts’ growth forecasts and price targets for CYTK stock (It’s free!) >>>
What the Market Is Telling Us About CYTK Stock
The steep drop suggests investors are wrestling with a classic late-stage biotech trade-off. On one hand, CYTK has achieved first-in-class approvals for MYQORZO in the U.S. and Europe, opening a sizable obstructive HCM market.
The company also continues to advance other muscle-targeted programs that could add to its opportunity set. These tailwinds support a long-term growth narrative. On the other hand, CYTK’s financial profile remains deeply in the red. Recent figures show negative gross margin and EBIT margin as launch and R&D costs far exceed revenue.
Returns on equity and invested capital are also negative, reflecting a stockholders’ deficit and ongoing losses. That combination means valuation is very sensitive to how quickly revenue ramps and expenses moderate. Upcoming catalysts could help clarify the story. CYTK is expected to report fiscal-year 2025 details again on February 27, 2026, and then Q1 2026 results on May 6, 2026.
These updates should show the early trajectory of MYQORZO prescriptions and reimbursement in both the U.S. and Europe. Conference appearances, including recent presentations at J.P. Morgan’s Healthcare Conference, also give management chances to refine expectations.
Estimate a company’s fair value instantly (Free with TIKR) >>>
Should You Invest in Cytokinetics, Incorporated?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up CYTK, and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track CYTK alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Analyze Cytokinetics stock on TIKR Free→
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
